Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FOLFIRI as a Second-line Therapy in Patients With Docetaxel-pretreated Gastric Cancer

NCT03486379 is registered in ClinicalTrials.gov with IRCCS Cancer Referral Center of Basilicata as lead sponsor.

NCT NCT03486379
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03486379 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FOLFIRI as a Second-line Therapy in Patients With Docetaxel-pretreated Gastric Cancer
Lead sponsor
IRCCS Cancer Referral Center of Basilicata
Phase
Observational
Overall status
Completed
Start date
March 31, 2016
Completion date
March 23, 2018
Enrollment
26 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, ramucirumab, third line